Роутима 0,5% 5 мл капли глазные

Nazione: Kirghizistan

Lingua: russo

Fonte: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Principio attivo:

Тимолол

Commercializzato da:

Роутек Лимитед (Rowtech Limited) (Роутек Лимитед (Rowtech Limited))

Codice ATC:

S01ED01

INN (Nome Internazionale):

Timolol

Dosaggio:

0,5% 5 мл

Forma farmaceutica:

капли глазные

Confezione:

№1

Tipo di ricetta:

по рецепту

Prodotto da:

Скан Биотек Лимитед (Scan Biotech Limited) (Индия)

Dettagli prodotto:

ПЖВЛС: нет

Data dell'autorizzazione:

2017-12-30

Scheda tecnica

YTBEPXAAIO
Ilepnufi
3aMecrrrreirb
ArrpenTopa
[euaprarueHTa
JreKapcrBeuHoro
o6ecue.reg[q
u MeAuIlrancKofi'
TexHIrKlr
MuHucrepcrBa 3ApaBooxpaHeHlrs
Krrprsrscnoii P
Ayftur
(
I,IHCTPyKIIUq
rro MEAI{III4HCKOMy
IIPI,IMEHEHI,IIO JIEKAPCTBEHHO|
O
CPENCTBA
Topronoe
Ha3BaHlre
Poyrnlra
POYTI4MA
MexcayuapoAHoe
HerrareHToBaHHoe
Ha3BaHIre
Tulrolon
JlenapcrneHHafl
Sopua
Kanrz rJra3Hble
Cocrae
B1 lrr [penapara coAep]Kr4Tcs:
Arcmuauoe
seLl{ecm6o:
Tulrorora Manear
6,8lrr
B [epecrrere
Ha
rrrMorror
5,0 ur.
B
c
no;vo
zam
e
rbHbr
e
6
e
We
cm6
a'.
BeHsanxoHr{r
xnopr4A
(n
nu4e 50Yo
pacrcopa)
0,2
Mr B nepecqere
Ha 100%
BelrlecrBo
0,1rtt,
Harpr4fl
4rarz4poSocSara4vru4par
0,1lur,
[unarpLls.
$oc$araoaeKarl,IApar
2,9
Mr,
AprHurpufl:.4.e'raraqnrvqpm
0,02 Mr, Harpuq
xnopr4A
7,I
wrr,Harprrfl
rrrApoKclrA
0,4 ut, BoIa
Ant
uureruuft.qo 1 un.
Ouucaulre
flpo:paunufi 6ecueerHr,rft
pacrnop.
2017
r.
Bera
-
OapmaroreparreBTr.rqecKas
rpyrrrra
Odlra,rrnronofr{ecKr.re
rpelaparbr.
llpo'rnnofrrayKoMHbre
npelaparbr
H Mr4orr4Krr.
a4peuo6noKaropbr.
Tuuonor.
Kor ATX:
S01ED01
(rapuanororrrqecKrre
csoiicrea
4)apuarcoduH(LtruKa
Tuuoro:r
trBJr.rrercr
HeceneKTr4BHbrM
6loxaroporra
6era-a4penopeqerrropoB,
He o6raAaer
eHyrpeuueft cr{MrraroMrrrr,rerraqecxofi
lr
uelr6panocta1utmzupyrouefi
aKTr,rBHocrbro.
llpu
MeoTHOM
npIrMeHeHHIr
B
BIrAe
fJIa3HbIX
KarIeJIb
TIIMOJIOJI
CHH)KaeT
KaK
HOpManbHOe,
TaK
I4
rIoBbIIIIeHHoe
BHyrprrrJra3Hoe
AaBneHrie
3a
crrer
yMeHbrrreHrax
o6pa:oBanns.
nuyrpurla:uofi
)Kr{AKocrrr.
[eficreue
rrTMoJroJraMaJreara
peanlr3yercr
3a cqer o6paruuoro
cBq3brBaHus.
c 6eta-
aApeHopeqerrropoM,
r{To
npr4Bo,4rzr
K uuru6HponaHr.r}o ero
peqerrropnofi
rfynrqrara u 6loxaAe
6r.ro.norn.iecrcofi crrrMynrqr{r4
perlerlTopoB,
B
coorBercrBr,rr4 c
yKa3aHHbrM
MexaHI,r3MoM
KoHr(ypeHTHofo
aHTaroHr43Ma
[por4cxoAr4r
6roraAa
oHAoreHHbrx r,r
gK3oreHHbx
crr,rMyJroB,
eo:4eficreyrcurrx
ua 6era-aqpeHopeqenropbr.
BroxaAa
6era-a4peuopeqerrropon lroxer
6rrrr
KynrrpoBaHa
rrocpeAcTBoM
rroBbIIIreHI4q
KoHIIeHTpaIII4I4
afoHl'IcroB
6era-a4peHopeqenropoB,
r{To
rrpr,rBeAer
K BoccraHoBJIeHkIIo
$yuxqu